周 俊良

Medicine & Life Sciences

1. Self Expandable Metallic Stents 100%
2. Cryotherapy 70%
3. Bronchoscopy 69%
4. Asthma 57%
5. Neutrophils 54%
6. Lung 53%
7. Non-Small Cell Lung Carcinoma 49%
8. Coronavirus 49%
9. Survival 48%
10. Erlotinib Hydrochloride 43%
11. BCL2-related protein A1 41%
12. Biopsy 40%
13. Stents 39%
14. Bronchi 39%
15. Taiwan 38%
16. Pneumonia 36%
17. Oxidants 35%
18. Respiratory Insufficiency 34%
19. Interleukin-5 Receptors 34%
20. Confidence Intervals 33%
21. Surgical Instruments 32%
22. Airway Obstruction 31%
23. Bronchoscopes 31%
24. ciclesonide 29%
25. Interleukin-5 29%
26. Cohort Studies 28%
27. Severe Acute Respiratory Syndrome 28%
28. Gefitinib 27%
29. Lung Neoplasms 26%
30. Pleural Effusion 26%
31. human ELANE protein 26%
32. Granulation Tissue 26%
33. Cell Death 25%
34. HL-60 Cells 25%
35. Odds Ratio 25%
36. Pleural Tuberculosis 25%
37. Extravascular Lung Water 25%
38. Up-Regulation 24%
39. Neoplasms 24%
40. Drug Therapy 24%
41. Defensins 23%
42. Apoptosis 23%
43. Myeloid-Derived Suppressor Cells 22%
44. Artificial Intelligence 22%
45. anti-IgE antibodies 22%
46. Acute Lung Injury 22%
47. Alveolar Epithelial Cells 21%
48. Budesonide 21%
49. ErbB Receptors 21%